Active	Status	Sponsor type	Region	Phase	Filter
8 Active 8 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Gerber, David
NCT03808558: Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas	Active, not recruiting	2	18	US	TVB-2640	David E Gerber, Sagimet Biosciences Inc., Cancer Prevention Research Institute of Texas, Gateway for Cancer Research	KRAS Gene Mutation	04/25	12/26
NCT02922777: Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.	Completed	1	23	US	BGB324, Docetaxel, Taxotere	University of Texas Southwestern Medical Center, Texas Tech University Health Sciences Center, BerGenBio ASA	Non-Small Cell Lung Carcinoma	02/23	04/23